Company Profile

Telix Pharmaceuticals Limited (NASDAQ: TLX)
8:00 PM UTC, 03/28/25
Last: $17.24 Change: -0.27 %Change: -1.54% Volume: 27,211
Detailed Quote
Open: $ 17.51   Volume: 27,211
High: $ 17.82   Yield(%) 0.00
Low: $ 17.24   P/E Ratio (ttm): 184.10
Dividend ($): n/a   Market Cap ($): 5.91B
EPS ($) 0.04   Shares Out: 337.71M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -7.35
% Price Change (last 13 weeks): 6.38
% Price Change (last 26 weeks): n/a
% Price Change (last 52 weeks): n/a
% Price Change (year to date): 13.70
Management Effectiveness
Return on Equity (%): 14.52
Return on Assets (%): 5.40
Return on Invested Capital (%): -90.92
Profitability
Gross Profit Margin (%): 65.16
Net Profit Margin (%): 6.37
Operating Profit Margin (%): 10.47
Price & Volume
50-day Moving Average: $17.89
200-day Moving Average: $n/a
Avg. Daily Vol. (last 50 days): 36,217
Avg. Daily Vol. (last 200 days): n/a
52-wk high: $n/a
52-wk low: $n/a
Bid: $15.00
Ask: $18.45
Company Information
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Telix Pharmaceuticals Limited
55 Flemington Road Suite 401 North Melbourne
Melbourne VI 3051

Phone: 61.3.9093.3855
Fax: n/a
http://www.telixpharma.com
Per Share Data
Earnings (1year) ($): 0.10
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): 184.10
Book Value ($): 1.05
Cash Flow ($): 0.11
Valuation Ratios
Price/Earnings (x): 184.10
Price/Sales (x): 10.29
Price/Book (x): 14.65
Price/Cash Flow (x): 187.30
Financial Strength
Quick Ratio (x): 2.66
Current Ratio (x): 2.78
LT Debt/Equity (x): 98.55
Total Debt/Equity (x): 102.33



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.